12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

625

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Olodaterol (BI1744)
DRUG: Olodaterol (BI1744)
DRUG: placebo

Sponsor

Boehringer Ingelheim